These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28564644)

  • 1. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton Pump Inhibitors and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: Results from the Japan Dialysis Outcomes and Practice Patterns Study.
    Nakashima A; Miyawaki Y; Komaba H; Kurita N; Onishi Y; Yokoo T; Fukagawa M
    Am J Nephrol; 2024; 55(2):165-174. PubMed ID: 37935135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
    Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
    Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
    Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
    Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
    Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China.
    Sui Z; Wang M; Zuo L
    Medicine (Baltimore); 2019 Jan; 98(2):e13981. PubMed ID: 30633179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using dynamic treatment regimes to understand erythropoietin-stimulating agent hyporesponsiveness.
    Pollack AH; Oron AP; Flynn JT; Munshi R
    Pediatr Nephrol; 2018 Aug; 33(8):1411-1417. PubMed ID: 29619552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
    Hasegawa T; Zhao J; Bieber B; Zee J; Pisoni RL; Robinson BM; Hanafusa N; Nangaku M
    Kidney Blood Press Res; 2021; 46(3):352-361. PubMed ID: 33887741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
    Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
    Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.